From the 65th American Society of Hematology Annual Meeting:
Patients given zanubrutinib for relapsed/refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma continue to have better PFS than their ibrutinib-treated counterparts after 3 years
Welcome to OncologyPRO – educational and scientific content for ESMO Members. Participants of some ESMO Meetings will have access to the Meeting resources section—limited to the meeting you attended. To gain full access to all the resources on this website, you must be an ESMO Member.
Please sign in using the username and password you created. To ensure a seamless browsing experience, we suggest that you sign in at the start of your visit.